Solid Biosciences (NASDAQ:SLDB) Posts Earnings Results, Beats Estimates By $0.01 EPS

Solid Biosciences (NASDAQ:SLDB) announced its earnings results on Thursday. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.01, Zacks reports.

Solid Biosciences Stock Down 1.3%

Shares of NASDAQ SLDB opened at $7.03 on Friday. The stock’s 50 day moving average price is $6.43 and its two-hundred day moving average price is $5.79. Solid Biosciences has a 52-week low of $2.41 and a 52-week high of $8.72. The stock has a market capitalization of $547.71 million, a P/E ratio of -3.48 and a beta of 2.65.

Key Headlines Impacting Solid Biosciences

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Guggenheim started coverage with a Buy and a $26 price target (implies ~272% upside from recent levels), giving formal street-level momentum and a large upside case for the stock. Guggenheim starts coverage (Benzinga)
• Positive Sentiment: Needham reaffirmed Buy with a $19 price target, signaling continued analyst conviction in the company’s clinical progress and longer-term value. Needham reaffirms buy (Benzinga)
• Positive Sentiment: Chardan reaffirmed its Buy rating and $15 target, adding to the cluster of upgrade/reaffirmation headlines that can attract investor attention and trading demand. Chardan reaffirms buy (TickerReport)
• Positive Sentiment: Solid reported positive interim Phase 1/2 INSPIRE data for SGT-003 at the 2026 MDA meeting; the readout highlights generally favorable tolerability in 41 dosed participants—this is the primary fundamental catalyst supporting higher valuations. SGT-003 interim data (GlobeNewswire)
• Neutral Sentiment: The company issued its Q4 and full-year 2025 results and broader business updates; the release contains operational context and program timelines that investors will parse for runway and development plans. Q4 & full-year 2025 results (FinanzNachrichten)
• Negative Sentiment: SLDB missed Q4 EPS expectations (reported -$0.53 vs. consensus -$0.48), underlining ongoing losses and near-term profitability risk that likely capped the stock’s upside today. Earnings press release (Quartr)

Insider Buying and Selling at Solid Biosciences

In other Solid Biosciences news, CEO Alexander Cumbo sold 16,644 shares of Solid Biosciences stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $5.82, for a total value of $96,868.08. Following the completion of the transaction, the chief executive officer owned 235,405 shares of the company’s stock, valued at $1,370,057.10. The trade was a 6.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Jessie Hanrahan sold 12,348 shares of the stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $6.44, for a total transaction of $79,521.12. Following the sale, the insider directly owned 70,327 shares in the company, valued at $452,905.88. This trade represents a 14.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 597,672 shares of company stock worth $3,816,546. 1.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Solid Biosciences

Several institutional investors have recently made changes to their positions in SLDB. AQR Capital Management LLC bought a new stake in shares of Solid Biosciences in the 1st quarter worth approximately $418,000. Goldman Sachs Group Inc. grew its stake in Solid Biosciences by 32.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 180,137 shares of the company’s stock worth $667,000 after buying an additional 43,910 shares during the last quarter. Woodline Partners LP acquired a new stake in Solid Biosciences in the first quarter worth $2,338,000. Creative Planning bought a new stake in Solid Biosciences in the second quarter valued at $57,000. Finally, JPMorgan Chase & Co. lifted its stake in Solid Biosciences by 111.1% in the second quarter. JPMorgan Chase & Co. now owns 34,379 shares of the company’s stock valued at $167,000 after buying an additional 18,094 shares during the last quarter. 81.46% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on SLDB shares. Weiss Ratings restated a “sell (d-)” rating on shares of Solid Biosciences in a research note on Thursday, January 22nd. Wedbush reissued an “outperform” rating and issued a $14.00 price target on shares of Solid Biosciences in a report on Wednesday, March 11th. Chardan Capital restated a “buy” rating and set a $15.00 price objective on shares of Solid Biosciences in a report on Friday. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 target price on shares of Solid Biosciences in a research report on Friday. Finally, Guggenheim started coverage on shares of Solid Biosciences in a research report on Friday. They set a “buy” rating and a $26.00 price target for the company. Eleven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $16.00.

About Solid Biosciences

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.